Pelvic floor dysfunction

World Lupus Federation Global Survey Finds 91% of People with Lupus Report Using Oral Steroids to Treat Lupus

Retrieved on: 
月曜日, 5月 6, 2024
Pain, Inflammation, Patient, Kidney, Weight gain, Risk, Skin, Blood, Heart, Diabetes, Lupus, Insomnia, Paratriathlon, Osteoporosis, Steroid, Joint, Disease, MPH, Infection, Immune system, Prednisone, Pelvic floor dysfunction, Dietary supplement

WASHINGTON, May 6, 2024 /PRNewswire/ -- A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus. Over 7,700 people living with lupus from more than 100 countries participated in the survey.

Key Points: 
  • WASHINGTON, May 6, 2024 /PRNewswire/ -- A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus.
  • The World Lupus Federation established World Lupus Day on May 10 to unite lupus groups around the world during Lupus Awareness Month and call attention to the disease's impact on the millions of people globally affected by lupus.
  • As we approach World Lupus Day, it is crucial that we continue to advocate for improved access to safe and effective treatments for lupus.
  • The World Lupus Federation is encouraging people around the globe on May 10 for World Lupus Day to share facts about lupus, including from this survey, and raise awareness using the official World Lupus Day Toolkit .

World Lupus Federation Global Survey Finds 91% of People with Lupus Report Using Oral Steroids to Treat Lupus

Retrieved on: 
月曜日, 5月 6, 2024
Pain, Inflammation, Patient, Kidney, Weight gain, Risk, Skin, Blood, Heart, Diabetes, Lupus, Insomnia, Paratriathlon, Osteoporosis, Steroid, Joint, Disease, MPH, Infection, Immune system, Prednisone, Pelvic floor dysfunction, Dietary supplement

WASHINGTON, May 6, 2024 /PRNewswire/ -- A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus. Over 7,700 people living with lupus from more than 100 countries participated in the survey.

Key Points: 
  • WASHINGTON, May 6, 2024 /PRNewswire/ -- A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus.
  • The World Lupus Federation established World Lupus Day on May 10 to unite lupus groups around the world during Lupus Awareness Month and call attention to the disease's impact on the millions of people globally affected by lupus.
  • As we approach World Lupus Day, it is crucial that we continue to advocate for improved access to safe and effective treatments for lupus.
  • The World Lupus Federation is encouraging people around the globe on May 10 for World Lupus Day to share facts about lupus, including from this survey, and raise awareness using the official World Lupus Day Toolkit .

Bridging Healthcare Gaps: The Wonder Woman Collective Unveils a New Vision for Women's Health

Retrieved on: 
金曜日, 5月 3, 2024
PCOS, Health equity, Urinary incontinence, Wonder, Infertility, Health, McKinsey & Company, Partnership, Human, Research, Pelvic floor dysfunction, Pelvic floor, Grammatical mood, Hypothyroidism, IVF, Entrepreneurship, Mental health, Patient, Work, Mother, Diagnosis, Migraine, Menopause, Quality of life, Nursing

With a shared commitment to innovation and excellence, this is the start of a foundation where future companies can join and redefine the standard of care in women's health. "With this initiative, we forge a new path in healthcare - one where comprehensive care, innovation, and patient-centricity are not just ideals, but realities. This is where the future of women's health begins." said Elizabeth Burstein, Co-Founder and CEO of Neura Health. Tina Keshani, Founder and CEO of Seven Starling adds "Women deserve specialized and tailored healthcare solutions to address their unique needs -- and no one company can do it all. "

Key Points: 
  • Five leading women's health companies, Paloma Health, Neura Health, LEVY Health, Seven Starling and Origin, have joined forces to announce The Wonder Woman Collective.
  • This strategic partnership addresses critical gaps in women's healthcare, focusing on improving healthcare outcomes, promoting health equity, reducing costs, and enhancing women's health.
  • "Addressing the Women's Health Gap is not just an option but a critical necessity.
  • "Through The Wonder Woman Collective, we are unifying diagnostic expertise and specialized care, enhancing the patient's journey and offering timely, comprehensive solutions," said Caroline Mitterdorfer, Co-Founder and CEO of LEVY Health.

AUA, SUFU Release Guideline on Diagnosis and Treatment of Overactive Bladder

Retrieved on: 
火曜日, 4月 23, 2024
Society, Phenotype, Woman, American Urological Association, MD, Partnership, Pelvic floor dysfunction, Guideline, OAB, Obesity, Patient, Overactive bladder, AUA, Constipation, Diagnosis, SUFU, Quality of life, Prevalence, Systematic review, Medical device

BALTIMORE, April 23, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released the 2024 clinical practice guideline for the diagnosis and treatment of overactive bladder (OAB).

Key Points: 
  • BALTIMORE, April 23, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released the 2024 clinical practice guideline for the diagnosis and treatment of overactive bladder (OAB).
  • As OAB is a symptom-based diagnosis, the impact of the symptoms on quality of life is critical to the condition.
  • The degree of bother caused by OAB symptoms directly affects OAB care-seeking, treatment intensity, and satisfaction with treatment.
  • The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder.

Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement

Retrieved on: 
月曜日, 4月 15, 2024
Sale, Brain, Pain, Myalgia, Stroke, Woman, Tissue, Dietary supplement, Infertility, Infection, Testosterone, DSM-IV codes, Pelvic floor dysfunction, Male, Climacteric, Insomnia, System, Dementia, Dysmenorrhea, Erectile dysfunction, Lipid, Anxiety, Toothache, Oxygen, Headache, Acquisition, Memory, Libido, Tribulus terrestris, Tracheobronchitis, Fever, Metamizole

HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.

Key Points: 
  • HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.
  • The acquisition includes full dossiers for each product, which will allow NKPH to quickly register them for sale once the company has finalized the branding of each.
  • The technologies, which were purchased through NKPH’s subsidiary, Nika Europe Ltd., have a proven market track record, as each of them satisfy an important health need of the population.
  • MENTHYL VALERATE 60mg is an over-the-counter drug with a positive effect on the central nervous and cardiovascular systems.

Makana™ Issued Patent in South Korea for Its Genetically-Modified TKO Pig for Use in Xenotransplantation

Retrieved on: 
水曜日, 5月 1, 2024
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, University, Genetics, National Kidney Foundation, Food, Kidney failure, Makana, Immunosuppression, Doctor of Philosophy, Jackson Memorial Hospital, Medicine, FACS, Organ transplantation, Patent, Massachusetts General Hospital, TKO, Patient, MTI, Kidney, Maryland School, Immune system, Clinical trial, Therapy, Quality of life, Pelvic floor dysfunction, Pharmaceutical industry

Makana™ Therapeutics, a global leader in the field of xenotransplantation, was granted an important patent in South Korea that will catalyze xenotransplantation efforts in that country, the company announced today.

Key Points: 
  • Makana™ Therapeutics, a global leader in the field of xenotransplantation, was granted an important patent in South Korea that will catalyze xenotransplantation efforts in that country, the company announced today.
  • The South Korean patent was granted on Makana’s Triple Knockout pig, or “TKO,” which is a combination of three xenoantigen gene knockouts in the pig that effectively camouflage the cross-species grafts from the human recipient’s immune system.
  • Platt added, “The Triple Knockout Pig has fundamentally changed the field and has moved xenotransplantation closer to becoming a clinically available reality.
  • “The TKO pig is widely seen as the preferred genetic profile that will enter clinical trials,” Platt said.

Health Equity in Transplantation Coalition Demands to Know Why Expert Physicians' Advice Was Ignored in Medicare Cuts for Life-Saving Blood Tests for Transplant Patients

Retrieved on: 
月曜日, 4月 22, 2024
Pain, CMS, Fox News, Kidney, Risk, The Wall Street Journal, Travel, Cover-up, Health, Heart, Transplant, Coalition, Life, FOIA, Congressional Black Caucus, Federation, Griot, Oportunidades, Science, MAC, USA Today, Patient, Politics, Physician, Dialysis, Kimberley Strassel, Health equity, Medicare, Freedom, Biopsy, CAC, MSNBC, Lung, Government, Anxiety, Pelvic floor dysfunction, Hill, Letter, Pharmaceutical industry

NEW YORK, April 22, 2024 /PRNewswire/ -- The Health Equity in Transplantation Coalition (HEiTC) and its partners are urging the federal government to address the discrepancy revealed by a Freedom of Information Act (FOIA) request: that the decision by Medicare contractors to limit coverage of blood tests blatantly contradicted the recommendations given by the government's own panel of medical experts. HEiTC's renewed call comes on the heels of a blistering Wall Street Journal editorial condemning the decision of the Medicare contractors to ignore the experts' recommendations. HEiTC continues to demand that Medicare contractors abolish ties to biopsies for coverage of these life-saving tests, which can detect a possible organ transplant rejections months before symptoms start to show.

Key Points: 
  • "Instead of listening to these experts and considering what these tests meant to tens of thousands of transplant recipients, the contractor not only ignored but withheld their expert opinion.
  • It's never been more important that these cutbacks are reversed and coverage without any tie to a biopsy is restored."
  • The new information shows that private Medicare contractors failed to disclose and then ignored the near-unanimous advice of expert physicians – handpicked by the contractors—to evaluate the evidence for non-invasive transplant rejection testing.
  • There was broad consensus from these expert clinicians that the testing had significant clinical utility including for routine, surveillance testing.

Sepsis Alliance Applauds Reintroduction of Lulu's Law in Advance of Pediatric Sepsis Week

Retrieved on: 
木曜日, 4月 18, 2024
Congress, Patient, Personality, Stroke, System, Sepsis Alliance, United, Amputation, Sepsis, Convulsion, Hope, Hospital, Skin, Death, House, Legislation, Eye, Representative, Cost, Lethargy, Rash, Memory, Diagnosis, Pelvic floor dysfunction, Infection

WASHINGTON, April 18, 2024 /PRNewswire-PRWeb/ -- A bill named in memory of four-year-old Ana Lucía "Lulu" Haynes, who passed away from sepsis in 2014, has been reintroduced in the House of Representatives. It arrives ahead of next week's Pediatric Sepsis Week observance, which provides an annual opportunity to raise awareness of the symptoms of sepsis in children and honor the 75,000 children who, like Lulu, develop sepsis in the U.S. each year. The Sepsis Harm and Cost Reduction Act, or Lulu's Law, develops a U.S. strategy for responding to sepsis and launches a program of state-based information repositories to improve sepsis diagnosis, treatment, and outcomes. This will help to answer the many unanswered questions about this condition, improve our ability to diagnose and treat it, and organize the country's strategy for solving sepsis. The legislation is championed by Sepsis Alliance, the nation's first and leading sepsis organization, and jointly sponsored by Representative Mikie Sherrill (D-NJ-11), who represents Lulu's district, and Representative Larry Bucshon, M.D. (R-IN-08).

Key Points: 
  • The Sepsis Harm and Cost Reduction Act, or Lulu's Law, develops a U.S. strategy for responding to sepsis and launches a program of state-based information repositories to improve sepsis diagnosis, treatment, and outcomes.
  • According to Sepsis Alliance, children, particularly those under five, can be especially susceptible to developing sepsis.
  • "That's why, this Pediatric Sepsis Week, it is so heartening to see the reintroduction of Lulu's Law, a serious effort to tackle the enormous national burden of sepsis.
  • Sepsis Alliance applauds and sincerely thanks Representative Sherrill and Representative Bucshon for their leadership on this vital bill."

75% OF WOMEN AGES 18-59 EXPERIENCED MULTIPLE PELVIC HEALTH ISSUES IN THE PAST YEAR ACCORDING TO A NEW STUDY BY ORIGIN AND IPSOS

Retrieved on: 
水曜日, 4月 17, 2024
Pelvis, News, Woman, Urinary incontinence, Constipation, Ipsos, Depression, Pelvic floor, Origin, PFD, Pelvic floor dysfunction, Gen, Mental health, Patient, Pelvic pain, Movement, Anxiety, Prevalence, Birth control

LOS ANGELES, April 17, 2024 /PRNewswire/ -- Origin, the leading nationwide provider of pelvic floor and women's health physical therapy, today released the "2024 Origin Pelvic Health Study," conducted by market research firm Ipsos and made possible by funding organized by Rise Together Ventures.

Key Points: 
  • LOS ANGELES, April 17, 2024 /PRNewswire/ -- Origin, the leading nationwide provider of pelvic floor and women's health physical therapy, today released the "2024 Origin Pelvic Health Study," conducted by market research firm Ipsos and made possible by funding organized by Rise Together Ventures .
  • The study reveals a hidden pelvic health crisis among women ages 18-59, not just for Gen X women, but also a shockingly high number of Millennials as young as 27.
  • Reported symptoms include bladder and bowel issues, sexual dysfunction, and pelvic pain.
  • At Origin, 9 out of 10 of patients report an improvement in pelvic floor symptoms.

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

Retrieved on: 
木曜日, 3月 21, 2024
Research, Other Health, General Health, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Pelvic floor dysfunction, MGH, Kidney disease, Gene, Organization, Survival, Massachusetts General Hospital, Transplant, Inflammation, Immunosuppression, Kidney failure, Mortality, Coagulation, Hope, Doctor of Philosophy, Expanded access, Quality of life, Genome, Transgene, Hospital, Kidney, Dialysis, CD40L, Courage, Kidney transplantation, Medicine, Dentistry

eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.
  • Following the procedure, the patient is in good condition and recovering well at MGH.
  • Yet the demand for organs far outpaces supply, with more than 90,000 individuals on the kidney waitlist and approximately 25,000 kidney transplants performed each year.
  • Decades of progress in cross-species transplantation, accelerated by the advancement of modern genome editing tools and next-generation sequencing, have enabled eGenesis to progress genetically engineered organs to the clinical setting.